Vitaliya S. Dizik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Vitaliya S. Dizik has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Marina A. Dzhavakhyan
All-Russian Scientific Research Institute of Medicinal and Aromatic Plants
2 shared publications - A. A. Markaryan
Yevdokimov Moscow State University of Medicine and Dentistry
1 shared publication - D. R. Dzhavakhyan
Yevdokimov Moscow State University of Medicine and Dentistry
1 shared publication - Denis Vladimirovich Kurkin
Russian University of Medicine. 2. Volgograd State Medical University
1 shared publication - Elena Igorevna Kalenikova
Lomonosov Moscow State University
1 shared publication - Evgeniy I. Morkovin
Volgograd State Medical University
1 shared publication
Latest Publications
- Open Access
- 5 October 2026
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 25 (3) , 101-110
Development of the composition and technology of pastilles with eutectic extract of leaves of Bupleurum aureum L.
Background. The use of eutectic solvents, whose formation is driven by the creation of a supramolecular network of hydrogen bonds, enables highly efficient extraction of biologically active substances from plant materials. In previous studies, the authors obtained a eutectic extract from the leaves of Bupleurum aureum L. and demonstrated its gastroprotective activity. Aim. To develop a novel pharmaceutical form (pastilles) based on the highly effective eutectic extract of Bupleurum aureum L. The research focuses on substantiating the choice of an oral dosage form and selecting an optimal composition of excipients to ensure pleasant organoleptic properties, which is a strategic direction for improving patient compliance. Materials and methods. The previously obtained eutectic extract of Bupleurum aureum L. (rutin content – 1.493 mg / ml, chlorogenic acid – 0.716 mg / ml) was used as the active substance. Excipients: ethyl alcohol (96 %, GOST R 5962–2013, Russia), agar-agar 900 (E406) (S-Chief SFC-014, Russia), apple pectin (S-Chief SFC-015, Russia), medical gelatin (Xiamen Gelken Gelatin Co, China), sodium carboxymethylcellulose (TU 2231-034-79249837-2006), food-grade alginate (GOST 33310–2015), guar gum (GOST 33310–2015), xanthan gum (E415) (GOST 33310–2015), food-grade citric acid (GOST 908–2004), carnauba wax (E903) (GOST 33310–2015). Development of pastilles formulations with extract was conducted in accordance with the definitions and requirements of the Russian Pharmacopoeia. Results. Based on organoleptic characteristics, the optimal combination of base-forming components was selected – agar and pectin (2 % each). The concentration and type of moisture-retaining excipient were established by assessing the drying rate of experimental samples. Taste correctors and lozenge coating were selected using a modified method by A. I. Tenzova. Conclusion. An optimal formulation for pastilles based on the liquid eutectic extract of Bupleurum aureum L. has been developed, comprising agar, pectin, xanthan gum, glucose syrup, and citric acid. The developed composition ensures the stability of the dosage form and the correction of organoleptic properties to enhance patient compliance.
- 5 October 2026
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 25 (3) , 101-110
Open AccessDevelopment of the composition and technology of pastilles with eutectic extract of leaves of Bupleurum aureum L.
Background. The use of eutectic solvents, whose formation is driven by the creation of a supramolecular network of hydrogen bonds, enables highly efficient extraction of biologically active substances from plant materials. In previous studies, the authors obtained a eutectic extract from the leaves of Bupleurum aureum L. and demonstrated its gastroprotective activity. Aim. To develop a novel pharmaceutical form (pastilles) based on the highly effective eutectic extract of Bupleurum aureum L. The research focuses on substantiating the choice of an oral dosage form and selecting an optimal composition of excipients to ensure pleasant organoleptic properties, which is a strategic direction for improving patient compliance. Materials and methods. The previously obtained eutectic extract of Bupleurum aureum L. (rutin content – 1.493 mg / ml, chlorogenic acid – 0.716 mg / ml) was used as the active substance. Excipients: ethyl alcohol (96 %, GOST R 5962–2013, Russia), agar-agar 900 (E406) (S-Chief SFC-014, Russia), apple pectin (S-Chief SFC-015, Russia), medical gelatin (Xiamen Gelken Gelatin Co, China), sodium carboxymethylcellulose (TU 2231-034-79249837-2006), food-grade alginate (GOST 33310–2015), guar gum (GOST 33310–2015), xanthan gum (E415) (GOST 33310–2015), food-grade citric acid (GOST 908–2004), carnauba wax (E903) (GOST 33310–2015). Development of pastilles formulations with extract was conducted in accordance with the definitions and requirements of the Russian Pharmacopoeia. Results. Based on organoleptic characteristics, the optimal combination of base-forming components was selected – agar and pectin (2 % each). The concentration and type of moisture-retaining excipient were established by assessing the drying rate of experimental samples. Taste correctors and lozenge coating were selected using a modified method by A. I. Tenzova. Conclusion. An optimal formulation for pastilles based on the liquid eutectic extract of Bupleurum aureum L. has been developed, comprising agar, pectin, xanthan gum, glucose syrup, and citric acid. The developed composition ensures the stability of the dosage form and the correction of organoleptic properties to enhance patient compliance.
- Open Access
- 8 December 2023
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 16 (4) , 630-642
Investigating the current state of the Russian market for drugs treating infectious and inflammatory conditions of oral cavity and oropharynx to demonstrate the need for new drug development
Objective: to assess the relevance and commercial prospects of bringing to market a drug for the local treatment of infectious and inflammatory diseases of oral cavity and oropharynx.Material and methods. The objects of the study were the drug nomenclatures in the State Register of Medicines, the Register of Medicines of Russia, as well as data from the Federal Service for Surveillance in Healthcare. The analysis of scientific publications in the field of marketing research of drugs, found in eLibrary.ru and PubMed/MEDLINE databases was carried out. For analyzing the structure and marketing research of drugs in the study group, specific methods of information retrieval, content analysis, description, data aggregation, ranking, data grouping method, system approach, as well as such methods of marketing analysis as determining the breadth and depth of the assortment, the renewal index, the vital importance index, SWOT analysis (strengths, weaknesses, opportunities, threats) were used.Results. The assortment of drugs for the local treatment of oral cavity and oropharyngeal infectious and inflammatory diseases was structured by the nature of the active substance, type of dosage form, and country of origin. The main trends in the development of the market of drugs of this group were identified. An analysis of the range of drugs using marketing research methods made it possible to establish the breadth and completeness of the range. The calculated renewal and vitality indices confirmed the relevance of developing new drugs with the considered pharmacotherapeutic action.Conclusion. The study revealed the main trends in the development of the market of drugs of the action in question. The SWOT analysis showed a possible strategy for developing and launching a new drug on the market.
- 8 December 2023
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 16 (4) , 630-642
Open AccessInvestigating the current state of the Russian market for drugs treating infectious and inflammatory conditions of oral cavity and oropharynx to demonstrate the need for new drug development
Objective: to assess the relevance and commercial prospects of bringing to market a drug for the local treatment of infectious and inflammatory diseases of oral cavity and oropharynx.Material and methods. The objects of the study were the drug nomenclatures in the State Register of Medicines, the Register of Medicines of Russia, as well as data from the Federal Service for Surveillance in Healthcare. The analysis of scientific publications in the field of marketing research of drugs, found in eLibrary.ru and PubMed/MEDLINE databases was carried out. For analyzing the structure and marketing research of drugs in the study group, specific methods of information retrieval, content analysis, description, data aggregation, ranking, data grouping method, system approach, as well as such methods of marketing analysis as determining the breadth and depth of the assortment, the renewal index, the vital importance index, SWOT analysis (strengths, weaknesses, opportunities, threats) were used.Results. The assortment of drugs for the local treatment of oral cavity and oropharyngeal infectious and inflammatory diseases was structured by the nature of the active substance, type of dosage form, and country of origin. The main trends in the development of the market of drugs of this group were identified. An analysis of the range of drugs using marketing research methods made it possible to establish the breadth and completeness of the range. The calculated renewal and vitality indices confirmed the relevance of developing new drugs with the considered pharmacotherapeutic action.Conclusion. The study revealed the main trends in the development of the market of drugs of the action in question. The SWOT analysis showed a possible strategy for developing and launching a new drug on the market.